Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
J Neurosci (2011) 31:658794
A 2025 safety study confirmed IV BPC-157 was well tolerated in healthy adults with no adverse events
Exendin-4 administration reduced visceral hypersensitivity in a dose-dependent manner and decreased serotonin levels in the colon
By promoting fatty acid metabolism, it enhances cardiovascular efficiency, which is vital for both general health and endurance performance
Consequently, this escalating global burden of obesity is fueling the expansion of the market for GLP-1 agonist weight loss pharmaceuticals
Kastenmller are co-inventors (through Duke University/Helmholtz Zentrum Mnchen) on patents on applications of metabolomics in diseases of the central nervous system and hold equity in Chymia LLC and IP in PsyProtix and Atai that are exploring the potential for therapeutic applications targeting mitochondrial metabolism in treatment-resistant depression
US$ 23.85
US$ 22.31
US$ 22.22
